AEZS-108: A targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 891-899

  Engel, Joerg ^a   Emons, Guenter ^b   Pinski, Jacek ^c   Schally, Andrew V ^d  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AEZS 108; Bladder cancer; Breast cancer; Doxorubicin; Endometrial cancer; LHRH receptor positive cancers; Ovarian cancer; Personalized medicine; Prostatic cancer; Targeted chemotherapy

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; THYROTROPIN;

ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CONFOCAL LASER MICROSCOPY; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOCYTOSIS; ENDOMETRIUM CANCER; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; HEART DISEASE; HORMONE BLOOD LEVEL; HUMAN; IC 50; IN VIVO STUDY; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VOMITING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS; RECEPTORS, LHRH;

EID: 84861040329     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.685128     Document Type: Review

References (45)

1. Schally AV, Engel JB, Emons G, et al. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 2011;8:11-25
2. Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157-67 (Pubitemid 46146968)
3. Schally AV, Comaru-Schally AM, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91 (Pubitemid 33010742)
4. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300-10 (Pubitemid 39193184)
5. Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA 2000;97:829-34 (Pubitemid 30070395)
6. Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-73 (Pubitemid 26243538)
7. Halmos G, Nagy A, Lamharzi N, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 1999;136(2):129-36 (Pubitemid 29164387)
8. Westphalen S, Kotulla G, Kaiser F, et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000;17:1063-9
9. Gunthert AR, Grundker C, Bongertz T, et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004;191:1164-72 (Pubitemid 39421567)
10. Grundker C, Volker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002;187:528-37
11. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20 (Pubitemid 36287676)
12. Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009;90:15-18
13. Engel JB, Schally AV, Dietl J, et al. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007;4:652-8 (Pubitemid 350004264)
14. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137-47 (Pubitemid 20199263)
15. Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003;9:3742-8 (Pubitemid 37169243)
16. Kahan Z, Nagy A, Schally AV, et al. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 2000;59:255-62 (Pubitemid 30243047)
17. Buchholz S, Seitz S, Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. Int J Oncol 2009;35:789-96
18. Foest C, Duwe F, Hellriegel M, et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 2011;25:1481-7
19. Emons G, Ortmann O, Becker M, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-46 (Pubitemid 23342164)
20. Emons G, Pahwa GS, Brack C, et al. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989;25:215-21 (Pubitemid 19054823)
21. Srkalovic G, Schally AV, Wittliff JL, et al. Presence and characteristics of receptors for [D-Trip6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489-98 (Pubitemid 28097966)
22. Volker P, Grundker C, Schmidt O, et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002;186:171-9 (Pubitemid 34165428)
23. Miyazaki M, Nagy A, Schally AV, et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997;89:1803-9 (Pubitemid 27516235)
24. Arencibia JM., Schally AV, Krupa M, et al. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 2001;19:571-7
25. Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990;50:1841-6 (Pubitemid 20098831)
26. Emons G, Schroder B, Ortmann O, et al. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993;77:1458-64 (Pubitemid 24000896)
27. Engel JB, Keller G, Schally AV, et al. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 2005;83(Suppl 1):1125-33 (Pubitemid 40543496)
28. Halmos G, Arencibia JM, Schally AV, et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-9 (Pubitemid 30060537)
29. Liu S, Schally AV, Hawes D, et al. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancer following therapy with LH-RH agonists. Clin Cancer Res 2010;16(18):4675-80
30. Letsch M, Schally AV, Szepeshazi K, et al. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505-13 (Pubitemid 37248409)
31. Fekete M, Zalatnai A, Schally AV. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 1989;45:87-91 (Pubitemid 19143343)
32. Gruendker C, Ernst J, Reutter MD, et al. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Oncol Rep 2011;26:629-35
33. Buchholz S, Keller G, Schally AV, et al. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. PNAS 2006;103(27):10403-7 (Pubitemid 44051179)
34. Guenther E, Teifel M, Engel JB, et al. Targeting doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152). EJC Suppl 2006;4(12):159
35. Emons G, Kaufmann M, Gorchev G, et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-61
36. Emons G, Tomov S, Harter P, et al. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol ASCO Meeting abstr 2010;28(15 part 1):abstract 5035
37. Emons G, Sehouli J, Gorchev G, et al. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. EJC Suppl 2010;8/7:120
38. Liu SV, Liu S, Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011;20/6:769-78
39. Liu SV, Schally AV, Dorff T, et al. A phase I/II trial of AEZS-108 in castration-and taxane-resistant prostate cancer. Poster presentation [abstract #294]. At ESMO Congress; 24 September 2011; Stockholm
40. A phase I/II trial of AEZS-108 in urothelial cancer patients who failed platinum-chemotherapy. Available from: http://clinicaltrials.gov/ct2/show/ NCT01234519?term=azes+108&rank=2, 2011
41. American Cancer Society. Cancer Facts & Figures 2011. American Cancer Society, Atlanta; 2011
42. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81
43. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52(1):108-18 (Pubitemid 350265179)
44. Berger ER. Treatment options for the advanced asymptomatic prostate cancer patient: an active immunotherapy approach. Community Oncol 2007;4(7):447-51
45. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011;23(6):594-600